MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Sendsor Corp., Medway, Mass.
Sendsor is developing a wireless cardiac monitoring platform using real-time blood pressure, flow, oxygen and blood chemistry data as a diagnostic and early-warning system for cardiac health.
Doug Adams, President and Founder
Pedro Irazoqui, CSO
Eric Chow, Director of Development
Beth McHallam, Controller
The SendSor device is a wireless active monitoring platform containing on-board electronics that capture, filter, amplify and digitize data for better signal resolution, on-chip event detection and continuous operation with no external user input. Real-time blood pressure, flow, oxygen and blood chemistry data are compiled on a microchip. This data can serve as a diagnostic and early-warning system for cardiac health. The SendSor device can be placed within targeted vasculature independently or can even be attached to the outer surface of a regular or drug-eluting FDA-approved stent. A minimally-invasive catheter based implantation procedure allows the delivery of the monitoring implant to nearly any major vessel or targeted lesion of the body. If determined that a stent could be of additional benefit to the targeted delivery location, the stent could also maintain a patent vessel lumen while allowing contact between the electronic sensors and the blood supply. The stent-based antenna can also be used to magnify both wireless telemetry and power transfer for the implanted electronics. The Company has validated transcutaneous transmission through ex vivo/ and in vivo porcine studies and is ready to start animal and human studies using the device.
The system consists of three parts: The miniature cardiac pressure sensor, the wireless transmitter, and the FDA approved stent. The stent enables efficient data transfer from and to the device and serves as a good anchor for the device in the blood vessel. The implantable device can be attached as an upgrade to a typical stent surgical procedure and could provide clinicians with some idea of how well the stent is faring in the implanted environment. A proposed location of where the stent can be implanted is in the pulmonary artery, which allows direct measurements of pulmonary diastolic pressure and requires only a minimally invasive outpatient catheter based surgery.